N-MethylbenzylamineCAS# 103-67-3 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 103-67-3 | SDF | Download SDF |
PubChem ID | 7669 | Appearance | Oil |
Formula | C8H11N | M.Wt | 121.18 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | N-methyl-1-phenylmethanamine | ||
SMILES | CNCC1=CC=CC=C1 | ||
Standard InChIKey | RIWRFSMVIUAEBX-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C8H11N/c1-9-7-8-5-3-2-4-6-8/h2-6,9H,7H2,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Structure Identification | Chinese Journal of Chemical Physics, 2004, 17(1):61-64.Photochemical reactions of Hypocrellin A with dibenzylamine and N-methylbenzylamine.[Reference: WebLink]
|
N-Methylbenzylamine Dilution Calculator
N-Methylbenzylamine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 8.2522 mL | 41.2609 mL | 82.5219 mL | 165.0437 mL | 206.3047 mL |
5 mM | 1.6504 mL | 8.2522 mL | 16.5044 mL | 33.0087 mL | 41.2609 mL |
10 mM | 0.8252 mL | 4.1261 mL | 8.2522 mL | 16.5044 mL | 20.6305 mL |
50 mM | 0.165 mL | 0.8252 mL | 1.6504 mL | 3.3009 mL | 4.1261 mL |
100 mM | 0.0825 mL | 0.4126 mL | 0.8252 mL | 1.6504 mL | 2.063 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Scutebarbatine M
Catalog No.:BCN8327
CAS No.:960302-92-5
- Benzyl cinnamate
Catalog No.:BCN5042
CAS No.:103-41-3
- Ethyl cinnamate
Catalog No.:BCN5044
CAS No.:103-36-6
- Methyl cinnamate
Catalog No.:BCN5043
CAS No.:103-26-4
- Monobenzone
Catalog No.:BCC3818
CAS No.:103-16-2
- H-DL-Phg-OH
Catalog No.:BCC3317
CAS No.:103-01-5
- Trelagliptin succinate
Catalog No.:BCC2015
CAS No.:1029877-94-8
- INCB28060
Catalog No.:BCC3793
CAS No.:1029712-80-8
- Scutellaric acid
Catalog No.:BCN5843
CAS No.:102919-76-6
- MDL 73005EF hydrochloride
Catalog No.:BCC6636
CAS No.:102908-60-1
- Pexidartinib (PLX3397)
Catalog No.:BCC6405
CAS No.:1029044-16-3
- 17-Hydroxy sprengerinin C
Catalog No.:BCN2755
CAS No.:1029017-75-1
- Phenylacetic Acid
Catalog No.:BCC8349
CAS No.:103-82-2
- 4'-Methylacetanilide
Catalog No.:BCC8714
CAS No.:103-89-9
- Acetaminophen
Catalog No.:BCC5269
CAS No.:103-90-2
- Dehydroheliobuphthalmin
Catalog No.:BCN5844
CAS No.:103001-05-4
- Alterlactone
Catalog No.:BCN7261
CAS No.:1030376-89-6
- MK-4305
Catalog No.:BCC1760
CAS No.:1030377-33-3
- CTCE 9908
Catalog No.:BCC6366
CAS No.:1030384-98-5
- Ethyl 3-(pyridin-2-ylamino)propanoate
Catalog No.:BCC8973
CAS No.:103041-38-9
- Daptomycin
Catalog No.:BCC1057
CAS No.:103060-53-3
- MK-8245
Catalog No.:BCC2299
CAS No.:1030612-90-8
- AS 2034178
Catalog No.:BCC7996
CAS No.:1030846-42-4
- Bakuchiol
Catalog No.:BCN5845
CAS No.:10309-37-2
Immunocytochemical localization of DNA adducts induced by a single dose of N-nitroso-N-methylbenzylamine in target and non-target tissues of tumor formation in the rat.[Pubmed:1934264]
Carcinogenesis. 1991 Oct;12(10):1831-7.
The formation and short-term persistence of O6-methylguanine (O6-meGua) and 7-methylguanine (7-meGua) in individual cells of various target and non-target tissues for tumor induction in rats were examined after a single dose of N-nitroso-N-Methylbenzylamine (NMBzA). In the principal target organ, the esophagus, both adducts were observed at 6 h after 0.5, 1.0 and 2.5 mg NMBzA/kg in a dose-dependent manner in nuclei of epithelial cells only. Nuclear staining in this organ had apparently declined by 72 h and modified nuclei were found in the more differentiated cells located closer to the lumen. In epithelial cells of the tongue, another target organ of NMBzA, methylation at 6 h was also dose dependent. At 72 h nuclear staining was lower and again largely located in differentiated cells. In the liver, a non-target organ, O6-meGua was not detectable and 7-meGua-specific staining was weak, being only observed at 6 h after the highest dose. Dose-dependent DNA methylation was seen, both at 6 and 72 h, in other non-target organs such as lung (bronchiolar epithelial cells), trachea (epithelial and glandular cells) and nasal cavity (respiratory epithelial cells, ductal cells of the respiratory lamina propria and cells of Bowman glands of the olfactory lamina propria); the nuclei of the glandular cells were highly methylated. Visual inspection of lung, trachea and nasal cavity indicated no or only minor losses of O6-meGua and 7-meGua between 6 and 72 h. Microdensitometric determination of the nuclear staining at 6 and 72 h indicated that the promutagenic O6-meGua was partially lost from cells of the tongue epithelium but did persist in esophageal epithelial cells; 7-meGua was lost to a substantial extent from both tongue and esophagus. The present results imply that the organotropism of NMBzA is not uniquely determined either by the initial level or the short-term persistence of DNA methylation.
Unique inhibitory action of the synthetic compound 2-[N-(2-aminoethyl)-N-(5-isoquinolinesulfonyl)] amino-N-(4-chlorocinnamyl)-N-methylbenzylamine (CKA-1306) against calcium/calmodulin-dependent protein kinase I.[Pubmed:9744570]
Biochem Pharmacol. 1998 Aug 1;56(3):329-34.
A newly synthesized compound, 2-[N-(2-aminoethyl)-N-(5-isoquinolinesulfonyl)]amino-N-(4-chlorocinnamyl )-N-Methylbenzylamine (CKA-1306), was found to inhibit cyclic AMP-dependent protein kinase (PKA) and Ca2+/calmodulin-dependent protein kinase I (CaMK I) with IC50 values of 1.6+/-0.14 and 2.5+/-0.16 microM, respectively. In contrast, the established PKA inhibitors H-8 and H-89 inhibited CaMK I with relatively high IC50 values of >100 and 24.4+/-3.2 microM, respectively. An additional inhibitor, KN-62, against Ca2+/calmodulin-dependent protein kinase II (CaMK II) did not inhibit either PKA or CaMK I at the concentrations tested. In our library of many isoquinolinesulfonamide derivatives, only CKA-1306 inhibited CaMK I to a satisfactory degree, suggesting a unique mode of action. Indeed, the inhibition of CaMK I by CKA-1306 was competitive in every respect to Mg2+/ATP, peptide substrate (syntide-2), and Ca2+/calmodulin. This phenomenon may be understood from the context of the recently determined structure of the enzyme in its autoinhibited state. Such kinetic analysis was also extended to cases using a phosphorylated and activated enzyme at Thr177 or a constitutively active, COOH-terminal truncated mutant at Gln293. CKA-1306 still competed with Mg2+/ATP for the two enzymes, but it no longer achieved any competitive advantage over syntide-2. These results may reflect some differences in the active conformation of CaMK I. However, the compound should be constant in its recognition of an Mg2+/ATP-binding site of the enzyme. Though CKA-1306 is not specific to CaMK I, the compound will be useful in studying the enzyme further under limited conditions.
KN-93 (2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N -methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels.[Pubmed:16368898]
J Pharmacol Exp Ther. 2006 Apr;317(1):292-9.
The effect of Ca(2+)/calmodulin-dependent protein kinase II (CaMK II) on voltage-gated ion channels is widely studied through the use of specific CaMK II blockers such as 2-[N-(2-hydroxyethyl)]-N-(4methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-m ethylbenzylamine (KN-93). The present study demonstrates that KN-93 is a direct extracellular blocker of a wide range of cloned Kv channels from a number of different subfamilies. In all channels tested, the effect of 1 microM KN-93 was independent of CaMK II because 1 microM2-[N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylam ine, phosphate (KN-92), an inactive analog of KN-93, caused similar inhibition of currents. In addition, dialysis of cells with 10 microM CaMK II inhibitory peptide fragment 281-301 (CIP) had no effect on current kinetics and did not prevent the inhibitory effect of KN-93. The IC(50) for block of the Kv1.5 channel (used as an example to determine the nature of KN-93 block) was 307 +/- 12 nM. KN-93 blocked open channels with little voltage dependence that did not alter the V(1/2) of channel activation. Removal of P/C-type inactivation by mutation of arginine 487 to valine in the outer pore region of Kv1.5 (R487V) greatly reduced KN-93 block, whereas enhancement of inactivation induced by mutation of threonine 462 to cysteine (T462C) increased the potency of KN-93 by 4-fold. This suggested that KN-93 acted through promotion and stabilization of C-type inactivation. Importantly, KN-93 was ineffective as a blocker when applied intracellularly, suggesting that CaMK II-independent effects of KN-93 on Kv channels can be circumvented by intracellular application of KN-93.
Accumulation of O6- and 7-methylguanine in DNA of N-nitroso-N-methylbenzylamine-treated rats is restricted to non-target organs for N-nitroso-N-methylbenzylamine-induced carcinogenesis.[Pubmed:1423882]
Carcinogenesis. 1992 Nov;13(11):2101-5.
The distribution and accumulation of O6-methylguanine (O6-meGua) and 7-methylguanine (7-meGua) was investigated immunocytochemically in target and non-target tissues of rats injected twice weekly with 0.5 mg N-nitroso-N-Methylbenzylamine (NMBzA)/kg for 16.5 weeks. Seventy two hours after every two or three doses, two NMBzA-treated rats and one control rat were killed. Tissue-specific cell proliferation was investigated after two injections of bromodeoxyuridine (BrdU) to rats unexposed to NMBzA. Neither O6-meGua- nor 7-meGua-specific immunostaining could be observed in the target tissues for tumor induction, i.e. esophagus, tongue and forestomach. Accumulation of both O6-meGua and 7-meGua was found, however, in nasal, tracheal and bronchiolar epithelia and glands--tissues for which tumor induction by NMBzA has not been reported. An explanation for this phenomenon might be the relatively low levels of cellular proliferation we observed in the latter epithelia. The present results support the hypothesis that the tumorigenic organotropism of NMBzA is determined both by the level of DNA methylation and the proliferative capacity of the methylated cells.